The DOI matches its Crossref record; 47 of the 48 references it cites were found in a registry or an index.
Saroglitazar, a PPAR-α/γ agonist, for treatment of NAFLD: a randomized controlled double-blind phase 2 trial
Open accessAbstract
BACKGROUND AND AIMS: NAFLD is characterized by insulin resistance and dysregulated lipid and glucose metabolism. Saroglitazar, a dual peroxisome proliferator activated receptor-α/γ agonist, improves insulin sensitivity, and lipid and glycemic parameters. Saroglitazar improved NASH histology in animal studies. In this randomized controlled clinical trial, we evaluated the efficacy and safety of saroglitazar in patients with NAFLD/NASH. APPROACH AND RESULTS: were randomized in a 1:1:1:1 ratio to receive placebo or saroglitazar 1 mg, 2 mg, or 4 mg for 16 weeks. The primary efficacy endpoint was percentage change from baseline in ALT levels at week 16. Liver fat content (LFC) was assessed by MRI proton density fat fraction. The least-squares mean percent change from baseline in ALT at week 16 was -25.5% (5.8), -27.7% (5.9), and -45.8% (5.7), with saroglitazar 1 mg, 2 mg, and 4 mg, respectively, versus 3.4% (5.6) in placebo (P < 0.001 for all). Compared with placebo, saroglitazar 4 mg improved LFC (4.1% [5.9] vs. -19.7% [5.6]), adiponectin (-0.3 μg/mL [0.3] vs. 1.3 μg/mL [0.3]), homeostatic model assessment-insulin resistance (-1.3 [1.8] vs. -6.3 [1.7]), and triglycerides (-5.3 mg/dL [10.7] vs. -68.7 mg/dL [10.3]) (P < 0.05 for all). Saroglitazar 4 mg also improved lipoprotein particle composition and size and reduced lipotoxic lipid species. Saroglitazar was well-tolerated. A mean weight gain of 1.5 kg was observed with saroglitazar 4 mg versus 0.3 kg with placebo (P = 0.27). CONCLUSIONS: Saroglitazar 4 mg significantly improved ALT, LFC, insulin resistance, and atherogenic dyslipidemia in participants with NAFLD/NASH. (ClinicalTrials.gov identifier: NCT03061721.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Two Phase II trials have investigated the effects of saroglitazar, a PPARα/γ agonist, and found improvement of ALT and hepatic fat (measured via MRI‐PDFF) [57] but no improvement of NAS (primary endpoint: delta change of NAS from baseline to Week 24 biopsy) [58].”
From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [57]
The cited source says what the claim attributes to it.
In the citing paper
“Saroglitazar, a dual PPAR a / c agonist has been shown to improve insulin resistance, liver steatosis and liver enzymes 426 and is approved in India for the treatment of T2D and MASH.”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [426]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“This lack of basic information may have confounded true treatment effects and results in serious difficulties concerning cross-trial comparisons [240].”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [240]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Self-citation2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk
Goff, D. C., Lloyd-Jones, D. M., Bennett, G., Coady, S., D’Agostino, R. B., Gibbons, R., Greenland, P., Lackland, D. T., Levy, D., O’Donnell, C. J., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.005 · Cited by 4,945
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Self-citationVernon, G. C., Baranova, A. V., & Younossi, Z. M. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04724.x · Cited by 3,116
Nonalcoholic Fatty Liver Disease
Marchesini, G., Brizi, M., Bianchi, G., Tomassetti, S., Bugianesi, E., Lenzi, M., McCullough, A. J., Natale, S., Forlani, G., & Melchionda, N. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1844 · Cited by 2,581
Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease
Targher, G., Day, C. P., & Bonora, E. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0912063 · Cited by 1,907
Association of nonalcoholic fatty liver disease with insulin resistance
Marchesini, G., Brizi, M., Morselli‐Labate, A. M., Bianchi, G. P., Bugianesi, E., McCullough, A. J., Forlani, G., & Melchionda, N. (1999) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00271-5 · Cited by 1,570
Musso, G., Gambino, R., Cassader, M., & Pagano, G. (2010) · Annals of Medicine · doi:10.3109/07853890.2010.518623 · Cited by 1,304
Cited by
Sorted by citations
Tacke, F., Horn, P., Wai-Sun Wong, V., Ratziu, V., Bugianesi, E., Francque, S., Zelber-Sagi, S., Valenti, L., Roden, M., Schick, F., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.04.031 · Cited by 2,210
Aging and aging-related diseases: from molecular mechanisms to interventions and treatments
Guo, J., Huang, X., Dou, L., Yan, M., Shen, T., Tang, W., & Li, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01251-0 · Cited by 1,976
Targeting fibrosis: mechanisms and clinical trials
Zhao, M., Wang, L., Wang, M., Zhou, S., Lu, Y., Cui, H., Racanelli, A. C., Zhang, L., Ye, T., Ding, B., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01070-3 · Cited by 547
(2024) · Obesity Facts · doi:10.1159/000539371 · Cited by 545
Stefan, N., Yki‐Järvinen, H., & Neuschwander‐Tetri, B. A. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00318-8 · Cited by 470
Xu, X., Poulsen, K. L., Wu, L., Liu, S., Miyata, T., Song, Q., Wei, Q., Zhao, C., Lin, C., & Yang, J. B. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01119-3 · Cited by 387
Liver diseases: epidemiology, causes, trends and predictions
Gan, C., Yuan, Y., Shen, H., Gao, J., Kong, X., Che, Z., Guo, Y., Wang, H., Dong, E., & Xiao, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02072-z · Cited by 416
PPAR-γ signaling in nonalcoholic fatty liver disease: Pathogenesis and therapeutic targets
Chen, H., Tan, H., Wan, J., Zeng, Y., Wang, J., Wang, H., & Lu, X. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108391 · Cited by 342
Current treatment of non‐alcoholic fatty liver disease
Paternostro, R., & Trauner, M. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13531 · Cited by 305
Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)
Li, R., Zou, J., Ran, W., Qi, X., Chen, Y., Cui, H., & Guo, J. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1087260 · Cited by 347
NAFLD and NASH: etiology, targets and emerging therapies
Wei, S., Wang, L., Evans, P. C., & Xu, S. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.103910 · Cited by 219
Mantovani, A., Byrne, C. D., & Targher, G. (2022) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(21)00261-2 · Cited by 230
Novel therapeutic targets for cholestatic and fatty liver disease
Trauner, M., & Fuchs, C. D. (2022) · Gut · doi:10.1136/gutjnl-2021-324305 · Cited by 204
Negi, C. K., Babica, P., Bajard, L., Vašků, J. B., & Tarantino, G. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154925 · Cited by 196
Parlati, L., Régnier, M., Guillou, H., & Postic, C. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100346 · Cited by 201
Tang, S.-P., Mao, X., Chen, Y., Yan, L., Ye, L., & Li, S.-W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.870239 · Cited by 194
Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?
Huttasch, M., Roden, M., & Kahl, S. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155937 · Cited by 169
Sangro, P., de la Torre‐Aláez, M., Sangro, B., & D’Avola, D. (2023) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-023-00954-4 · Cited by 163
Todisco, S., Santarsiero, A., Convertini, P., Stefano, G. D., Gilio, M., Iacobazzi, V., & Infantino, V. (2022) · Biology · doi:10.3390/biology11050792 · Cited by 162
Fraile, J. M., Palliyil, S., Barelle, C. J., Porter, A. J., & Kovaleva, M. (2021) · Drug Design Development and Therapy · doi:10.2147/dddt.s315724 · Cited by 164
Portincasa, P., Khalil, M., Mahdi, L., Perniola, V., Idone, V., Graziani, A., Baffy, G., & Ciaula, A. D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115640 · Cited by 167
Clinical Trial Landscape in NASH
Harrison, S. A., Loomba, R. S., Dubourg, J., Ratziu, V., & Noureddin, M. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.03.041 · Cited by 142
Self-citationBreakthroughs in therapies for NASH and remaining challenges
Ratziu, V., Francque, S., & Sanyal, A. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.04.002 · Cited by 132
Vachliotis, I. D., & Polyzos, S. (2023) · Current Obesity Reports · doi:10.1007/s13679-023-00519-y · Cited by 115
Metabolic dysfunction-associated steatotic liver disease and the heart
Driessen, S., Francque, S., Anker, S. D., Cabezas, M. C., Grobbee, D. E., Tushuizen, M. E., & Holleboom, A. G. (2023) · Hepatology · doi:10.1097/hep.0000000000000735 · Cited by 133
Metabolic Changes of Hepatocytes in NAFLD
Lu, Q., Tian, X., Wu, H., Huang, J., Li, M., Mei, Z., Zhou, L., Xie, H., & Zheng, S. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.710420 · Cited by 118
Treating NASH by targeting peroxisome proliferator-activated receptors
Staels, B., Butruille, L., & Francque, S. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.07.004 · Cited by 114
Duseja, A. K., Singh, S. P., De, A., Madan, K., Rao, P. N., Shukla, A., Choudhuri, G., Saigal, S., Shalimar, S., Arora, A., et al. (2022) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2022.11.014 · Cited by 107
Non-Alcoholic Fatty Liver Disease in Lean and Non-Obese Individuals: Current and Future Challenges
Kuchay, M. S., Martínez‐Montoro, J. I., Choudhary, N. S., Fernández‐García, J. C., & Ramos‐Molina, B. (2021) · Biomedicines · doi:10.3390/biomedicines9101346 · Cited by 105
The role of lipid metabolism in osteoporosis: Clinical implication and cellular mechanism
Zhang, J., Hu, W., Zou, Z., Li, Y., Kang, F., Li, J., & Dong, S. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2023.101122 · Cited by 111
Nuclear receptors linking metabolism, inflammation, and fibrosis in nonalcoholic fatty liver disease
Puengel, T., Liu, H., Guillot, A., Heymann, F., Tacke, F., & Peiseler, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052668 · Cited by 95
Aspirin for Metabolic Dysfunction–Associated Steatotic Liver Disease Without Cirrhosis
Simon, T. G., Wilechansky, R. M., Stoyanova, S., Grossman, A., Dichtel, L. E., Lauer, G. M., Miller, K. K., Hoshida, Y., Corey, K. E., Loomba, R. S., et al. (2024) · JAMA · doi:10.1001/jama.2024.1215 · Cited by 96
Diet-induced gut dysbiosis and inflammation: Key drivers of obesity-driven NASH
Kang, G. G., Trevaskis, N. L., Murphy, A. J., & Febbraio, M. A. (2023) · iScience · doi:10.1016/j.isci.2022.105905 · Cited by 94
Current Options and Future Directions for NAFLD and NASH Treatment
Zhang, C., & Yang, M. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147571 · Cited by 97
Futile cycles: Emerging utility from apparent futility
Sharma, A. K., Khandelwal, R., & Wolfrum, C. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.03.008 · Cited by 91
Rao, G., Peng, X., Li, X., An, K., He, H., Fu, X., Li, S., & An, Z. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1294267 · Cited by 93
NASH drug treatment development: challenges and lessons
Tilg, H., Byrne, C. D., & Targher, G. (2023) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(23)00159-0 · Cited by 81
PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients
Lange, N. F., Graf, V., Caussy, C., & Dufour, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084305 · Cited by 84
Vuppalanchi, R., Caldwell, S. H., Pyrsopoulos, N., deLemos, A. S., Rossi, S., Levy, C., Goldberg, D. S., Mena, E. A., Sheikh, A., Ravinuthala, R., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.08.025 · Cited by 79
Self-citationDysregulation of Lipid and Glucose Metabolism in Nonalcoholic Fatty Liver Disease
Bhat, N., & Mani, A. (2023) · Nutrients · doi:10.3390/nu15102323 · Cited by 85
Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies
Kokkorakis, M., Muzurović, E. M., Volčanšek, Š., Chakhtoura, M., Hill, M. A., Mikhailidis, D. P., & Mantzoros, C. S. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.123.001087 · Cited by 79
Zhou, S., You, H., Qiu, S., Yu, D., Bai, Y., He, J., Cao, H., Che, Q., Guo, J., & Su, Z. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113577 · Cited by 71
Liver Fibrosis and MAFLD: From Molecular Aspects to Novel Pharmacological Strategies
Qu, W., Ma, T., Cai, J., Zhang, X., Zhang, P., She, Z., Wan, F., & Li, H. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.761538 · Cited by 71
Kamata, S., Honda, A., & Ishii, I. (2023) · Biomolecules · doi:10.3390/biom13081264 · Cited by 71
Musso, G., Saba, F., Cassader, M., & Gambino, R. (2023) · Progress in Lipid Research · doi:10.1016/j.plipres.2023.101238 · Cited by 71
Díaz, L. A., Arab, J. P., Idalsoaga, F. J., Perelli, J., Vega, J. A., Dirchwolf, M., Carreño, J., Samith, B., Valério, C. M., Moreira, R. O., et al. (2025) · Annals of Hepatology · doi:10.1016/j.aohep.2025.101903 · Cited by 72
Chen, Y., Wang, W., Morgan, M. P., Robson, T., & Annett, S. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1148934 · Cited by 63
The Role of Nuclear Receptors in the Pathogenesis and Treatment of Non-alcoholic Fatty Liver Disease
Yang, Z., Danzeng, A., Liu, Q., Zeng, C., Xu, L., Mo, J., Ciren, P., Wang, X., Wang, C., Zhang, B., et al. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.87305 · Cited by 61
A Molecular Insight into the Role of Antioxidants in Nonalcoholic Fatty Liver Diseases
Ezhilarasan, D., & Thangavelu, L. P. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/9233650 · Cited by 63
Armandi, A., & Bugianesi, E. (2024) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2024.01.005 · Cited by 62
Gong, L., Wei, F., Gonzalez, F. J., & Li, G. (2023) · Hepatology · doi:10.1097/hep.0000000000000182 · Cited by 61
Treating inflammation to combat non-alcoholic fatty liver disease
Wiering, L., & Tacke, F. (2022) · Journal of Endocrinology · doi:10.1530/joe-22-0194 · Cited by 59
Michalopoulou, E., Thymis, J., Lampsas, S., Pavlidis, G., Katogiannis, K., Vlachomitros, D., Katsanaki, E., Kostelli, G., Pililis, S., Pliouta, L., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14020428 · Cited by 69
Autophagy and hepatic lipid metabolism: mechanistic insight and therapeutic potential for MASLD
Raza, S., Rajak, S., Yen, P. M., & Sinha, R. A. (2024) · npj Metabolic Health and Disease · doi:10.1038/s44324-024-00022-5 · Cited by 56
Ezhilarasan, D. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155912 · Cited by 54
Metabolic syndrome and its association with nonalcoholic steatohepatitis
Bril, F., Sanyal, A., & Cusi, K. (2023) · Clinics in Liver Disease · doi:10.1016/j.cld.2023.01.002 · Cited by 52
Self-citationUpdates on novel pharmacotherapeutics for the treatment of nonalcoholic steatohepatitis
Yang, Y., Xie, L. H., Zhang, N., Zhou, D., Liu, T., & Wu, J. H. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-00860-3 · Cited by 53
MASLD/MASH and type 2 diabetes: Two sides of the same coin? From single PPAR to pan-PPAR agonists
Cooreman, M. P., Vonghia, L., & Francque, S. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111688 · Cited by 55
Pharmacotherapy for Non-Alcoholic Fatty Liver Disease: Emerging Targets and Drug Candidates
Александровна, П. В., Bezborodkina, N. N., & Okovityi, S. V. (2022) · Biomedicines · doi:10.3390/biomedicines10020274 · Cited by 55
Cariou, B. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14651 · Cited by 57
MASLD treatment—a shift in the paradigm is imminent
Machado, M. V. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1316284 · Cited by 51
MASH clinical trials and drugs pipeline: An impending tsunami
Noureddin, M. (2024) · Hepatology · doi:10.1097/hep.0000000000000860 · Cited by 54
Self-citationFerdous, S.-E., & Ferrell, J. M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168731 · Cited by 56
Chew, N., Ng, C. H., Muthiah, M. D., & Sanyal, A. J. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01027-5 · Cited by 49
Amin, N. B., Saxena, A. R., Somayaji, V., & Dullea, R. (2023) · Clinical Therapeutics · doi:10.1016/j.clinthera.2022.12.008 · Cited by 48
Circadian Regulation of Gene Expression and Metabolism in the Liver
Guan, D., & Lazar, M. A. (2022) · Seminars in Liver Disease · doi:10.1055/a-1792-4240 · Cited by 48
Shared Mechanisms between Cardiovascular Disease and NAFLD
Huang, D. Q., Downes, M., Evans, R. M., Witztum, J. L., Glass, C. K., & Loomba, R. S. (2022) · Seminars in Liver Disease · doi:10.1055/a-1930-6658 · Cited by 46
Souza-Tavares, H., Miranda, C. S., Vasques‐Monteiro, I. M. L., Sandoval, C., Santana-Oliveira, D. A., Silva-Veiga, F. M., Fernandes‐da‐Silva, A., & Souza‐Mello, V. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i26.4136 · Cited by 51
Pal, P., Palui, R., & Ray, S. (2021) · World Journal of Hepatology · doi:10.4254/wjh.v13.i11.1584 · Cited by 51
MASLD development: From molecular pathogenesis toward therapeutic strategies
Yang, Z., Zhao, J., Xie, K., Tang, C., Gan, C., & Gao, J. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003629 · Cited by 49
Nonalcoholic Steatohepatitis Drug Development Pipeline: An Update
Chew, N., Ng, C. H., Truong, E., Noureddin, M., & Kowdley, K. V. (2022) · Seminars in Liver Disease · doi:10.1055/a-1877-9656 · Cited by 44
Self-citationSiddiqui, M. S., Parmar, D., Sheikh, F., Sarin, S. K., Cisneros, L., Gawrieh, S., Momin, T., Duseja, A. K., & Sanyal, A. J. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.01.018 · Cited by 47
Self-citationFeng, X., Zhang, R., Yang, Z., Zhang, K., & Xing, J. (2024) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2024.00019 · Cited by 45
Tan, C. X. A., Li, R., Zhang, F., Dai, L., Ullah, N., & Lü, Y. (2022) · Angewandte Chemie International Edition · doi:10.1002/anie.202209494 · Cited by 41
Pharmacological treatment of MASLD: contemporary treatment and future perspectives
Drygalski, K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136518 · Cited by 39
Jiang, Y., Wu, L., Zhu, X., Bian, H., Gao, X., & Xia, M. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02092-2 · Cited by 46
Li, D., Ma, J.-M., Li, M., Gao, L., Fan, Y., Zhang, Y., Tao, X., & Yang, J. (2022) · Nutrients · doi:10.3390/nu14153247 · Cited by 40
Chaudhuri, S., Dutta, A., & Chakraborty, S. B. D. (2023) · JGH Open · doi:10.1002/jgh3.12878 · Cited by 38
Tantu, M. T., Farhana, F. Z., Haque, F., Koo, K. M., Qiao, L., Ross, A. G., & Shiddiky, M. J. A. (2025) · npj gut and liver. · doi:10.1038/s44355-025-00030-2 · Cited by 45
Brown, E. A., Minnich, A., Sanyal, A. J., Loomba, R. S., Du, S., Schwarz, J., Ehman, R. L., Karsdal, M. A., Leeming, D. J., Cizza, G., et al. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2022.100661 · Cited by 37
Impact of NAFLD and its pharmacotherapy on lipid profile and CVD
Wang, Z., Ye, M., Zhang, X., Zhang, P., Cai, J., Li, H., & She, Z. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.07.010 · Cited by 39
Mobasheri, L., Ahadi, M., Namdar, A. B., Alavi, M. S., Bemidinezhad, A., Farahi, S. M. M., Esmaeilizadeh, M., Nikpasand, N., Einafshar, E., & Ghorbani, A. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115502 · Cited by 41
Metformin and the Liver: Unlocking the Full Therapeutic Potential
Perazza, F., Leoni, L., Colosimo, S., Musio, A., Bocedi, G., D’Avino, M., Agnelli, G., Nicastri, A., Rossetti, C., Sacilotto, F., et al. (2024) · Metabolites · doi:10.3390/metabo14040186 · Cited by 39
Wang, S., Yin, J., Liu, Z., Liu, X., Tian, G., Xin, X., Qin, Y., & Feng, X. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.123211 · Cited by 42
Current Therapeutic Landscape for Metabolic Dysfunction-Associated Steatohepatitis
Devasia, A. G., Ramasamy, A., & Leo, C. H. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26041778 · Cited by 45
What’s New in the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD)
Kosmalski, M., Frankowski, R., Ziółkowska, S., Różycka-Kosmalska, M., & Pietras, T. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12051852 · Cited by 38
Wong, V. W., Amin, N. B., Takahashi, H., Darekar, A., Tacke, F., Kiszko, J., Rodriguez, H., Nakajima, A., Alkhouri, N., Charlton, M., et al. (2025) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(25)00128-1 · Cited by 37
Decoding organ fibrosis: mechanistic insights and emerging therapeutic strategies
Chen, X., Zhang, J., Guo, L., Wu, C., Zhou, J., Xu, M., Mo, L., Li, Y., & He, J. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02532-0 · Cited by 40
Bandyopadhyay, S. K., Samajdar, S. S., & Das, S. (2023) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2023.102174 · Cited by 35
Ali, H., Shahzil, M., Moond, V., Shahzad, M., Thandavaram, A., Sehar, A., Waseem, H., Siddiqui, T. A., Dahiya, D. S., Patel, P., et al. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14010061 · Cited by 40
Self-citationHepatocyte CYR61 polarizes profibrotic macrophages to orchestrate NASH fibrosis
Mooring, M., Yeung, G. A., Luukkonen, P., Liu, S., Akbar, M. W., Zhang, G. J., Balogun, O., Yu, X., Mo, R., Nejak-Bowen, K., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.ade3157 · Cited by 33
Roles and Mechanisms of Choline Metabolism in Nonalcoholic Fatty Liver Disease and Cancers
Chen, X., Qiu, W., Ma, X., Ren, L., Feng, M., Hu, S., Xue, C., & Chen, R. (2024) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2905182 · Cited by 36
Resmetirom: The First Disease‐Specific Treatment for MASH
Mousa, A. M., Mahmoud, M., & AlShuraiaan, G. M. (2025) · International Journal of Endocrinology · doi:10.1155/ije/6430023 · Cited by 37
Zhang, Z., Yang, H., Han, F., & Guo, P. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47060464 · Cited by 37
Honda, A., Kamata, S., Akahane, M., Machida, Y., Uchii, K., Shiiyama, Y., Habu, Y., Miyawaki, S., Kaneko, C., Oyama, T., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094726 · Cited by 32
Harris, S. J., Smith, N., Hummer, B., Schreibman, I. R., Faust, A. J., Geyer, N. R., Chinchilli, V. M., Sciamanna, C., Loomba, R., & Stine, J. G. (2024) · Liver International · doi:10.1111/liv.15769 · Cited by 31
Oligonucleotide therapies for nonalcoholic steatohepatitis
Li, S., Xiong, F., Zhang, S., Liu, J., Gao, G., Xie, J. H., & Wang, Y. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102184 · Cited by 32
Pharmacotherapy for metabolic dysfunction-associated steatohepatitis: heart–liver co-management
Zhou, X., Lazarus, J. V., Krittanawong, C., Targher, G., Byrne, C. D., Younossi, Z. M., Tacke, F., Chen, Q., Mantzoros, C. S., Tilg, H., et al. (2026) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(25)00323-1 · Cited by 35
Binet, Q., Loumaye, A., Preumont, V., Thissen, J., Hermans, M. P., & Lanthier, N. (2022) · Acta gastro-enterologica belgica · doi:10.51821/85.2.9775 · Cited by 35
Dai, J.-J., Zhang, Y., & Zhang, Z. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i37.5339 · Cited by 31
Metadata
- Authors
- Gawrieh, S., Noureddin, M., Loo, N., Mohseni, R., Awasty, V., Cusi, K., Kowdley, K. V., Lai, M., Schiff, E., Parmar, D., Patel, P., & Chalasani, N.
- Affiliations
- Indiana University School of Medicine (US)
- Cedars-Sinai Medical Center (US)
- Texas Liver Institute (US)
- Catalina Research Institute (US)
- Marion General Hospital (US)
- University of Florida Health (US)
- Liver Institute Northwest (US)
- Beth Israel Deaconess Medical Center (US)
- University of Miami (US)
- Zydus Discovery DMCC,Dubai,UAE
- Zydus Lifesciences Limited (India) (IN)
- Corresponding author
- Chalasani, Naga
- ORCID
- Venue
- Hepatology
- Published
- 2021-07-19
- Volume
- 74
- Issue
- 4
- Pages
- 1809-1824
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W3149930516
- Cited by
- 379
- References
- 48
- Citations by year
- 2026: 46 · 2025: 82 · 2024: 82 · 2023: 87 · 2022: 57 · 2021: 25
- FWCI
- 45.21
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Purdue University Indianapolis (Indiana University) (submittedVersion)
- IUScholarWorks (Indiana University) (submittedVersion)
- Funders
- Amgen
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Gilead Sciences
- Celgene
- Novo Nordisk
- Allergan
- Janssen Research and Development
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Keywords
- saroglitazar, non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, PPAR alpha/gamma agonist, insulin resistance, atherogenic dyslipidemia, liver fat, ALT, adiponectin, triglycerides, drug safety and tolerability, weight gain, PPARγ antagonist, PPARα
- MeSH terms
- Adipose Tissue, Adult, Alanine Transaminase, Alkaline Phosphatase, Aspartate Aminotransferases, Cholesterol, Double-Blind Method, Female, gamma-Glutamyltransferase, Humans, Insulin Resistance, Cholesterol, HDL, Cholesterol, LDL, Liver, Magnetic Resonance Imaging, Male, Middle Aged, Phenylpropionates, Pyrroles, Triglycerides, Cholesterol, VLDL, PPAR alpha, PPAR gamma, Elasticity Imaging Techniques, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
